Comparative Pharmacology
Head-to-head clinical analysis: CALAN versus NIMOTOP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALAN versus NIMOTOP.
CALAN vs NIMOTOP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.
Nimodipine is a dihydropyridine calcium channel blocker that selectively inhibits calcium influx into vascular smooth muscle cells, leading to vasodilation. It has a preferential effect on cerebral arteries, reducing the incidence of vasospasm following subarachnoid hemorrhage.
Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.
60 mg orally every 4 hours for 21 days, initiated within 96 hours of subarachnoid hemorrhage. If unable to swallow, 0.5 mg/h continuous IV infusion via central line; increase to 1 mg/h after 2 hours if tolerated, continue for up to 21 days.
None Documented
None Documented
Terminal elimination half-life is 3-7 hours for immediate-release; can be prolonged to 12-16 hours with sustained-release due to slow absorption; increased in hepatic impairment.
Terminal elimination half-life is approximately 8–9 hours (range 3–12 hours) in adults, with clinical context of twice-daily dosing for continuous cerebral vasodilation in subarachnoid hemorrhage.
Approximately 70% renal (3-4% unchanged, remainder as metabolites) and 25% biliary/fecal.
Primarily hepatic metabolism; 50% excreted in urine as metabolites, 30% in feces via biliary elimination. Less than 1% excreted unchanged in urine.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker